Royal Bank Of Canada Landos Biopharma, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.26 - $0.55 $71 - $151	-276 Reduced 72.82%	103 $0
Q4 2022 Feb 14, 2023	SELL	$0.22 - $0.51 $67 - $156	-306 Reduced 44.67%	379 $0
Q3 2022 Nov 14, 2022	BUY	$0.67 - $1.26 $229 - $430	342 Added 99.71%	685 $0
Q2 2022 Aug 15, 2022	SELL	$0.6 - $1.5 $87 - $217	-145 Reduced 29.71%	343 $0
Q1 2022 May 16, 2022	SELL	$1.44 - $5.22 $11,034 - $40,000	-7,663 Reduced 94.01%	488 $0
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $35,400 - $112,980	7,532 Added 1216.8%	8,151 $39,000
Q3 2021 Nov 15, 2021	BUY	$9.77 - $15.77 $1,719 - $2,775	176 Added 39.73%	619 $9,000
Q2 2021 Aug 16, 2021	BUY	$9.26 - $12.53 $4,102 - $5,550	443 New	443 $5,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.